START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism

NCT00132431 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Disease
Secondary Hyperparathyroidism
Chronic Kidney Disease

Interventions

DRUG: Sensipar

Sponsor

Amgen